Cargando…
Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentation?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261865/ https://www.ncbi.nlm.nih.gov/pubmed/37323182 http://dx.doi.org/10.21037/tlcr-23-97 |
| _version_ | 1785057961231515648 |
|---|---|
| author | Oya, Yuko Mitsudomi, Tetsuya |
| author_facet | Oya, Yuko Mitsudomi, Tetsuya |
| author_sort | Oya, Yuko |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10261865 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102618652023-06-15 Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentation? Oya, Yuko Mitsudomi, Tetsuya Transl Lung Cancer Res Editorial Commentary AME Publishing Company 2023-05-08 2023-05-31 /pmc/articles/PMC10261865/ /pubmed/37323182 http://dx.doi.org/10.21037/tlcr-23-97 Text en 2023 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Oya, Yuko Mitsudomi, Tetsuya Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentation? |
| title | Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentation? |
| title_full | Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentation? |
| title_fullStr | Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentation? |
| title_full_unstemmed | Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentation? |
| title_short | Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentation? |
| title_sort | is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentation? |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261865/ https://www.ncbi.nlm.nih.gov/pubmed/37323182 http://dx.doi.org/10.21037/tlcr-23-97 |
| work_keys_str_mv | AT oyayuko isadagrasibjustanothersotorasiborshouldwedifferentiatetheirusageaccordingtopatientsclinicalpresentation AT mitsudomitetsuya isadagrasibjustanothersotorasiborshouldwedifferentiatetheirusageaccordingtopatientsclinicalpresentation |